APOLLO: Personalized rehAbilitation PrOgram in aLLOgeneic Bone Marrow Transplantation

Allogeneic Disease Clinical Trial

— APOLLO  

Official title:

APOLLO: Personalized rehAbilitation PrOgram in aLLOgeneic Bone Marrow Transplantation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05579678
• Other study ID #: HREBA.CC-22-0164
• Status: Recruiting
• Start date: November 20, 2022
• Est. completion date: June 30, 2024

Study information

• Verified date: November 2023
• Source: University of Alberta
• Contact: Edith Pituskin, PhD
• Phone: 7804328221
• Email: pituskin[@]ualberta.ca
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

People who undergo allogeneic bone marrow transplant for blood cancers receive the highest chemotherapy doses possible that humans can receive and still survive. As a result, they have devastating side effects during the procedure and for many years afterwards. Damage to organs and muscles cause long-lasting physical weakness and the psychological experience is severe enough to be termed 'post traumatic stress disorder' that also lasts for many years. These effects are worsened by the fact that most Canadians live several hours away from treatment and transplant centers, leaving them entirely on their own to manage these difficult long term effects. The APOLLO team will perform a qualitative study to learn the experiences of people undergoing allogeneic bone marrow transplant while they receive access to a supportive care computer 'app' and telephone support from nursing, exercise and nutrition experts. In this way, the APOLLO team will learn the most helpful type and timing of supportive care from those who know best.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 45
• Est. completion date: June 30, 2024
• Est. primary completion date: June 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• eligible for allogeneic transplantation

Exclusion Criteria:

• none

Related Conditions & MeSH terms

• Allogeneic Disease

Intervention

Behavioral:
• Supportive nursing, nutritional and physical activity with a handheld 'app'
Supportive nursing, nutritional and physical activity with a handheld 'app'

Locations

Country	Name	City	State
Canada	University of Alberta	Edmonton	Alberta

Sponsors (1)

Lead Sponsor	Collaborator
University of Alberta

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Title: Acceptability of a multimodal supportive care	Description: Questionnaire to assess usefulness of a multimodal supportive care App that includes care navigation (nursing, exercise, nutrition)	1 year